Glenn N. Levine, MD

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

A total of 5,225 patients were enrolled in the PARAGON B trial. Among these patients, the type of heparin used was known in 5,200 (99.5%). The median duration of therapy was 72.8 hours for UFH and 79.7 hours for LMWH. LMWH was used in about...

A total of 5,225 patients were...

08/01/2008

Journal of Invasive Cardiology

Continuing Education

Pharmacoinvasive Management of Acute Coronary Syndrome:
Incorporating the 2007 ACC/AHA Guidelines

08/01/2008

Marc S. Cohen , MD;

Jose G. Diez , MD;

Sunil V. Rao , MD, FACC, FSCAI;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

David A. Morrow , MD, MPH;

Every year, more than 1 million patients are admitted to a hospital with a diagnosis of unstable angina or non-ST-elevation myocardial infarction (UA/NSTEMI).1 Relative to acute ST-elevation myocardial infarction (STEMI), patients with...

Every year, more than 1 million...

08/01/2008

Journal of Invasive Cardiology

Continuing Education

Strategies for Optimizing Outcomes in the NSTE-ACS Patient: The CATH (Cardiac Catheterization and Antithrombotic Therapy
in th

08/01/2008

Edward T.A. Fry , MD;

Sunil V. Rao , MD, FACC, FSCAI;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

Jacob Shani , MD;

Marc S. Cohen , MD;

Jose G. Diez , MD;

Target Audience: Clinical Cardiologists, Interventional Cardiologists and Nurses. Release Date: 12-01-06 Expiration Date: 11-30-07 Learning Objectives: Upon completion of this educational activity, participants should be able to: Educate...

Target Audience: Clinical...

08/01/2008

Journal of Invasive Cardiology

Continuing Education

Strategies for Optimizing Outcomes in the NSTE-ACS Patient: The CATH (Cardiac Catheterization and Antithrombotic Therapy
in th

08/01/2008

Marc S. Cohen , MD;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

Sunil V. Rao , MD, FACC, FSCAI;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

Jacob Shani , MD;

(PART II) A second group of patients who have received less attention were those who were switched at randomization; approximately three quarters of the patients were on some form of antithrombotic therapy prior to randomization — half of...

(PART II) A second group of...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Over the past decade, impressive reductions in mortality, reinfarction and length of hospital stay have been reported in large-scale studies of patients with acute coronary syndrome (ACS). Despite these advances, substantial challenges remain...

Over the past decade, impressive...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Part II of III - Continued TABLE 3 KEY (continued) 2) Unfractionated heparin(UFH) can be used as an alternative to enoxaparin. If UFH is used in the setting of PCI, activated clotting time (ACT) should be followed to achieve an appropriate...

Part II of III -...

08/01/2008

Journal of Invasive Cardiology